PPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Passaro, Angela ^a   Dalla Nora, Edoardo ^a   Marcello, Caterina ^a   Di Vece, Francesca ^a   Morieri, Mario L ^a   Sanz, Juana M ^a   Bosi, Cristina ^a   Fellin, Renato ^a   Zuliani, Giovanni ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

ACE I D; Fat distribution; Metabolic syndrome; Obesity; Polymorphism; PPAR 2; Pro12Ala

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DNA; GLUCOSE; INSULIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRIMER DNA;

ADULT; ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS; CAUCASIAN; DNA ISOLATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; AGED; AMINO ACID SUBSTITUTION; COHORT ANALYSIS; GENETICS; INDEL MUTATION; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AMINO ACID SUBSTITUTION; BASE SEQUENCE; BODY FAT DISTRIBUTION; BODY MASS INDEX; COHORT STUDIES; DNA PRIMERS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INDEL MUTATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA;

EID: 83355164487     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-112     Document Type: Article

References (47)

1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
3. Lin HF, Boden-Albala B, Juo SH, Park N, Rundek T, Sacco RL. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. Diabetologia 2005, 48:2006-2012.
4. Ide T, Egan K, Bell-Parikh LC, FitzGerald GA. Activation of nuclear receptors by prostaglandins. Thromb Res 2003, 110:311-315.
5. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest 2003, 112:945-955.
6. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997, 272:18779-18789.
7. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
8. Rangwala SM, Lazar MA. Transcriptional control of adipogenesis. Annu Rev Nutr 2000, 20:535-559.
9. Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992, 41:393-398.
10. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000, 106:467-472.
11. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270:12953-12956.
12. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997, 241:270-274.
13. Bouhaha R, Meyre D, Kamoun HA, Ennafaa H, Vaillant E, Sassi R, et al. Effect of ENPP1/PC-1-K121Q and PPARgamma-Pro12Ala polymorphisms on the genetic susceptibility to T2D in the Tunisian population. Diabetes Res Clin Pract 2008, 81:278-283.
14. Damcott CM, Moffett SP, Feingold E, Barmada MM, Marshall JA, Hamman RF, et al. Genetic variation in fatty acid-binding protein-4 and peroxisome proliferator-activated receptor gamma interactively influence insulin sensitivity and body composition in males. Metabolism 2004, 53:303-309.
15. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287.
16. Rosado EL, Bressan J, Martins MF, Cecon PR, Martinez JA. Polymorphism in the PPARgamma2 and beta2-adrenergic genes and diet lipid effects on body composition, energy expenditure and eating behavior of obese women. Appetite 2007, 49:635-643.
17. Fornage M, Jacobs DR, Steffes MW, Gross MD, Bray MS, Schreiner PJ. Inverse effects of the PPAR(gamma)2 Pro12Ala polymorphism on measures of adiposity over 15 years in African Americans and whites. The CARDIA study. Metabolism 2005, 54:910-917.
18. Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 2003, 40:773-780.
19. Ochoa MC, Marti A, Azcona C, Chueca M, Oyarzabal M, Pelach R, et al. Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents. Int J Obes Relat Metab Disord 2004, 28(Suppl 3):S37-S41.
20. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2010, 171:645-655.
21. Huguenin GV, Rosa G. The Ala allele in the PPAR-gamma2 gene is associated with reduced risk of type 2 diabetes mellitus in Caucasians and improved insulin sensitivity in overweight subjects. Br J Nutr 2010, 104:488-497.
22. Scacchi R, Pinto A, Rickards O, Pacella A, De Stefano GF, Cannella C, et al. An analysis of peroxisome proliferator-activated receptor gamma (PPAR-gamma 2) Pro12Ala polymorphism distribution and prevalence of type 2 diabetes mellitus (T2DM) in world populations in relation to dietary habits. Nutr Metab Cardiovasc Dis 2007, 17:632-641.
23. de Rooij SR, Painter RC, Phillips DI, Osmond C, Tanck MW, Defesche JC, et al. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on glucose/insulin metabolism interact with prenatal exposure to famine. Diabetes Care 2006, 29:1052-1057.
24. Hsieh MC, Lin SR, Hsieh TJ, Hsu CH, Chen HC, Shin SJ, et al. Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan. Nephrol Dial Transplant 2000, 15:1008-1013.
25. Tiret L, Blanc H, Ruidavets JB, Arveiler D, Luc G, Jeunemaitre X, et al. Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Projet d'Etude des Genes de l'Hypertension Arterielle Severe a moderee Essentielle. J Hypertens 1998, 16:37-44.
26. Pujia A, Gnasso A, Irace C, Dominijanni A, Zingone A, Perrotti N, et al. Association between ACE-D/D polymorphism and hypertension in type II diabetic subjects. J Hum Hypertens 1994, 8:687-691.
27. Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Bhansali A, Sud K, et al. ACE Variants Interact with the RAS Pathway to Confer Risk and Protection against Type 2 Diabetic Nephropathy. DNA Cell Biol 2009, 28:141-150.
28. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000, 35:1270-1277.
29. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
30. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992, 51:197-205.
31. Roszer T, Ricote M. PPARs in the Renal Regulation of Systemic Blood Pressure. PPAR Res 2010, 2010:698730.
32. John SW, Weitzner G, Rozen R, Scriver CR. A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res 1991, 19:408.
33. Solini A, Giacchetti G, Sfriso A, Fioretto P, Sardu C, Saller A, et al. Polymorphisms of angiotensin-converting enzyme and angiotensinogen genes in type 2 diabetic sibships in relation to albumin excretion rate. Am J Kidney Dis 1999, 34:1002-1009.
34. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2010, 171:645-655.
35. Cole SA, Mitchell BD, Hsueh WC, Pineda P, Beamer BA, Shuldiner AR, et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord 2000, 24:522-524.
36. Morini E, Tassi V, Capponi D, Ludovico O, Dallapiccola B, Trischitta V, et al. Interaction between PPARgamma2 variants and gender on the modulation of body weight. Obesity (Silver Spring) 2008, 16:1467-1470.
37. Gonzalez Sanchez JL, Serrano RM, Fernandez PC, Laakso M, Martinez Larrad MT. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002, 147:495-501.
38. Gray SL, Nora ED, Grosse J, Manieri M, Stoeger T, Medina-Gomez G, et al. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes 2006, 55:2669-2677.
39. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003, 52:910-917.
40. Wan J, Xiong S, Chao S, Xiao J, Ma Y, Wang J, et al. PPARgamma gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol 2010, 9:13.
41. Rosado EL, Bressan J, Martinez JA, Marques-Lopes I. Interactions of the PPARgamma2 polymorphism with fat intake affecting energy metabolism and nutritional outcomes in obese women. Ann Nutr Metab 2010, 57:242-250.
42. Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol 2011, 10:16.
43. Lee YJ, Tsai JC. ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. Diabetes Care 2002, 25:1002-1008.
44. Costa LA, Canani LH, Maia AL, Gross JL. The ACE insertion/deletion polymorphism is not associated with the metabolic syndrome (WHO Definition) in Brazilian type 2 diabetic patients. Diabetes Care 2002, 25:2365-2366.
45. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 2008, 105:6531-6536.
46. Eisenmann JC, Sarzynski MA, Glenn K, Rothschild M, Heelan KA. ACE I/D genotype, adiposity, and blood pressure in children. Cardiovasc Diabetol 2009, 8:14.
47. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001, 142:487-492.